Roche Diagnostics Leading and creating new markets

Transcription

1 Roche Leading and ceating new makets Heino von Pondzynski Head of Roche Goldman Sachs UK Roadshow London, May 14 th 2004

2 This pesentation contains cetain fowad-looking statements. These fowad-looking statements may be identified by wods such as believes, expects, anticipates, pojects, intends, should, seeks, estimates, futue o simila expessions o by discussion of stategy, goals, plans o intentions. Vaious factos may cause actual esults to diffe mateially in the futue fom those eflected in fowad-looking statements contained in this pesentation among othes: (1) picing and poduct initiatives of competitos; (2) legislative and egulatoy developments and economic conditions; (3) delay o inability in obtaining egulatoy appovals o binging poducts to maket; (4) fluctuations in cuency exchange ates and geneal financial maket conditions; (5) uncetainties in the discovey, development o maketing of new poducts o new uses of existing poducts; (6) inceased govenment picing pessues; (7) inteuptions in poduction; (8) loss of o inability to obtain adequate potection fo intellectual popety ights; (9) litigation; (10) loss of key executives o othe employees; and (11) advese publicity o news coveage. 2

3 Stong Opeational Pefomance Key Aeas of Focus of the Futue 3

4 Roche Clea maket leade Roche maket shae 1 20 % sales gowth 2 10 % Abbott 12 % -3 % J & J Baye* 8 % 10 % 4 % 4 % Beckman C. 7 % 12% Dade Behing IVD Maket 6 % 4 % 5 % 0% 5% 10% 15% 20% 0% 5% 10% 1 souce: company epots, Boston Biomedical Consultants, Roche analysis 2 in local cuencies, excludes Life Science eseach maket * based on 2003 esults 4

5 2004: Off to a good stat Double maket gowth continues gowth CHF m CHF m local CHF Diabetes Cae % 15 % Molecula (ex. ind. bus) % 14 % Centalized % 8 % Nea Patient Testing % 0 % Roche in vito 1,579 1, % 11 % Applied Science % 9 % Molecula Diag - industial business % 5 % Life Science business % 9 % Roche 1,725 1, % 11 % 5

6 Roche Pefomance Significant maket shae gains and impoved pofitability Sales Development * Maket Shae % Pofitability % M CHF 11% 14% % Othes Dade Behing Beckman C. Baye J&J Abbott RD Pofit magin EBITDA magin * 2001* % 19.0% New accounting ules 2003 *Including cash discounts Souce: Roche 6

7 Stong Opeational Pefomance Key Aeas of Focus of the Futue 7

8 Stategy Innovation is the key to gowth Key Objectives Cuent Business Futue Gowth Dives Stetching ou boundaies Ceating new makets Shaping ou maket space Developing ou futue gowth dives Ceating new segments Stengthening ou cuent business Setting the foundation of of futue gowth Aspiations Be among the top thee playes in each maket whee we choose to paticipate Expand maket shae leadeship in key focus aeas though technology/ poduct innovation Dive paadigm shifts though innovation; actionable health infomation, molecula medicine Attact, nutue, and gow global talent to havest futue leades 8

9 Roche Focusing on 3 key aeas Focus Diabetes Cae Molecula Immunochemisty Stategic diection innovative systems minimizing steps & impoving patient comfot Integated stip monitoing coss leveaging pumps & blood glucose monitoing blood glucose monitoing connectivity solutions atificial panceas infomation management algoithms fo bette health management 9

10 Blood glucose monitoing maket Roche Accu-Chek outpefoming competitos Roche J&J/ LifeScan Baye/ Ascensia Abbott/ Medisense local gowth % ex. Disetonic 1 % 2 % 3 % 15 % Accu-Chek Advantage Accu-Chek Active & Go Accu-Chek Compact Accu-Chek SoftClix Infusion Systems Q1 '04: CHF 710 million (+15 % local gowth) (+41 %) (+9 %) (n.a.)* (+9 %) (+2 %) bg Maket 5 % othe (-11 %) 0% 5% 10% 15% souce: Boston Biomedical Consultants, Company epots, Roche estimates * based on Q1 '03 Q1 '04 10

11 Diabetes Cae Stategy Focused on thee coe poduct aeas Connectivity solutions/ infomation management Innovative Blood Glucose Monitoing Systems Mete-Stip Systems Integated Systems Continuous Glucose Monitoing Systems Insulin Pump Systems New Business Initiatives 11

12 Roche Focusing on 3 key aeas Focus Diabetes Cae Stategic diection Expanding into new makets Blood sceening and Women s Health Molecula Molecula Immunochemisty Clinical Genomics Cance Ealy detection and patient statification Complex diseases Risk pediction and phamacogenomics 12

13 Molecula Roche the undisputed maket leade maket shae 2003* Molecula diagnostics: Q1 04: CHF 251 million (+14 % local gowth) Roche 49 % Blood Sceening (+38 %) Chion 15 % HIV quant (+1 %) Baye 7 % HCV qual/quant (+2 %) GenPobe 8 % CT/NG (+24 %) Abbott 7 % HBV quant (+30 %) BD 6 % industial business (+14 %) Digene 4 % othe (+10 %) 0% 25% 50% souce: Company Repots, Boston Biomedical Consultants, Roche analysis * Infectious diseases incl. HPV

14 Molecula Boadest test menu available Molecula viology/ Infectious diseases HIV HCV HBV CMV Tubeculosis Clinical diagnostics women s health CT/NG HPV (CE) oncology Ealy Detection - beast - coloectal -postate Tumo Pofiling - beast - coloectal -postate - leukemia genetics Facto II/ IV CYP 450 Cystic Fibosis Phamacogenomics Risk pediction Blood sceening HIV HCV HBV WNV HAV Pavo B19 appoved eseach/ ASR/ clinical tials in development 14

15 Human Papillomavius (HPV) New gowth oppotunity HPV maket potential Dec 03 Q CHF m test of cue sceening tiage AMPLICOR HPV (MWP) Detect all high-isk HPV stains Tiage and sceening CE mak Ap 04 Linea Aay HPV Genotypes 37 types of vius Epidemiology, vaccine tials, test of cue COBAS TaqMan 96/48 Quantitates vial levels Fully automated eal time PCR HPV positive sample Maket pojected to gow to >1 billion CHF 15

16 Roche Focusing on 3 key aeas Focus Diabetes Cae Molecula Stategic diection Diving system placements! Centalized & decentalized labs Elecsys E170, 2010, 1010 Developing novel makes PoBNP, CVD, poteomic makes (coloectal, beast cance & RA) Immunodiagnostics Simplifying wokflow and data management Seum Wok Aea 16

17 Immunodiagnostics Gaining maket in the lagest IVD segment ($6.1 bn) 2003 Immunodiagnostic Maket Shae 1 Abbott 25% gowth 2003 in % (local) -7 Roche Dade Behing 10% 14% Baye 9% +12 Beckmann Coulte DPC Bio- Meieux 7% 6% 5% % 10% 20% souce: Boston Biomedical Consultants epot, Company epots Roche estimates 1 w/o Blood Bank Testing 17

18 Roche R&D Pipeline Pe-milestone Milestone 1 Milestone 2 Milestone 3 Milestone 4 Myoc. Infaction pedisposition Colon Cance isk pediction Beast Cance isk pediction Beast Cance teatm. esponse AmpliChip Syst. Micoaay System Postate Cance ealy detection Colon Cance ealy detection Postate Cance mol. classification PCR Sepsis Autom. System ICAD Micofluidic PCR system Beast Cance ealy detection Osteopoosis pedisposition Rheum. Athitis pedisposition Only includes majo pojects Reseach Stoke Risk Pediction COBAS z200 integ. sp/amp/det Colon Cance ealy detection Beast Cance ealy detection Lung Cance ealy detection Rheum. Athitis diagnosis Atheoscleosis isk assessment Sepsis ealy detection and staging Anemia & Renal Disodes - diagnosis Live Cance diagnosis Stoke diffeential diagnosis Pulmonay Disodes diagnosis Fully Integ. Spot Monit. Syst. Osteo. COL1A1 pedisposition Micoaay HIV Genotype Leukemia micoaay cobas TaqMan CT/NG New geneation HCV genotyping HIV Potease inhibitos cobas c111 Refloton HES cobas c701 Clin. Chemisty Thombosis intevention statification Ischemia diagnosis CBIA aay technology New Hospital bgm System GlucOnline Cont. Monitoing Blood gas/cadiac Modul. Integ. System Poduct Development HPV TaqMan P53 micoaay Cobas s400 blood sceening cobas c311 Clin. Chemisty cobas e411 Immunochemisty New LIS POC Coagulation New System NT-poBNP POC Single Stip System Compact II Softclix Simplicity cobas TaqMan CT Linea Aay HCV Genotyping LightCycle Pt & FV cobas s200 bloodsceening Leukemia DSS Remote Infomation Gateway cobas c501 Clin. Chemisty Moay 1.0 D-TRONplus update High Thoughput LC Applied Science Molecula Centalized Diabetes Cae Nea Patient Testing HPV genotyping TaqMan HCV genotyping CE mak IVD LightCycle L220 Integated Cobas AmpliPep+CTM HIV, HCV, HBV P450 CE mak Elecsys HIV Comb CE mak New Insulin Pump Accu Chek GO Safe-T-Po Plus Advantage III DataCae Web Softwae CoaguCheck PT Stips Uisys 1100 IT poducts New Technologies 18

19 Beast cance Biomakes can potentially detect cance ealie than imaging BCM18 - Fist successful lead molecule fom poteomics initiative BCM18 shows a highe specificity and a compaable sensitivity to CA 15-3, the cuent tumo make fo beast cance The combination of BCM18 with CA 15-3 significantly inceases sensitivity* Twelve additional beast cance candidates unde validation to futhe incease sensitivity * Sensitivity of CA 15.3 = 24 %, combined BCM 18 and CA15.3 = 40 % 19

20 Diagnostic innovations fo 2004 STA CephaSceen (Coag) HPV MWP (CE mak) AmpliChip CYP450 (CE mak) HPV Linea Aay (CE mak) Elecsys P1NP Accu-Chek Safe T-Po Plus (lancing device) Elecsys HIV Combi Accu-Chek Softclix (new) TaqMan HCV genotyping (CE mak) IVD LightCycle L220 H1 H2 Elecsys S100 Linea Aay HCV genotyping (RUO) DataCae Web Softwae CoaguChek PT Stips D-TRON plus Uisys 1800 Integated Cobas AmpliPep + Cobas TaqMan HIV, HCV, HBV new pump Sensotend LC Hepes I & II (CE mak) TaqMan CT (CE mak) Linea Aay HCV Genotyping (CE mak) 20

21 Stong Opeational Pefomance Key Aeas of Focus of the Futue 21

22 Stategy Stetching ou boundaies and ceating new makets Key Initiatives Expand testing Phenotype and Genotype Expand maket place Fom IVD to actionable health infomation Cuent Business Futue Gowth Dives Aspiations 22

23 in clinical pactice Inceasing ole in management decisions Today Diagnosis Monitoing Tomoow 1. Risk pediction - what could happen? 2. Ealy detection - what is happening now? 3. Theapy pediction - what will happen? 4. Phamacogenomics - which theapy to use? Taditional test dug test Expand Testing Maket test test test test test/dug test Diagnosis Monitoing Pedisposition Testing Risk pediction and Pognosis What will happen next Tageted Monitoing Pevention Diagnosis Theapy Monitoing Poviding Health Infomation: Disease Risk Dug Choice Health Status Theapy Efficacy 23

24 Summay Roche is the leade in diagnostics, gowing significantly above the maket Expansion though stengthening coe businesses and ceating and shaping new makets Focusing on 3 high gowth, high pofit aeas diabetes cae, molecula diagnostics, immunochemisty Innovative technologies and pogams in place to extend leadeship in each aea Moe than 20 majo poduct launches planned fo 2004, with > 70 new poducts in the pipeline Roche well positioned to dive expansion into new untapped makets such as isk pediction, ealy detection and theapy pediction 24